Opus Genetics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from LifeSci Capital reiterated a Buy rating on the stock and has a $10.00 price target.

4th of July Sale - 70% Off

• Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
• Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Francois Brisebois has given his Buy rating due to a combination of factors tied to Opus Genetics’ clinical and regulatory progress. He highlights the recent agreement with the FDA on the pivotal Phase 3 trial design for OPGx-LCA5, noting that key elements such as patient number, bilateral dosing, and the six‑month run‑in period are now clearly defined and acceptable to regulators.

He also points to the strong Phase 1/2 efficacy signal, where retinal sensitivity gains exceeded the threshold set for the registrational endpoint, effectively de‑risking the upcoming Phase 3 program that is expected to start dosing in 4Q26. In parallel, he views OPGx-BEST1 as the main value driver and is focused on the September 2026 three‑month topline data, while acknowledging continued operational execution and multiple additional programs nearing the clinic. These factors, combined with a stable $10 price target and sufficient cash runway, underpin his decision to reiterate a Buy recommendation on IRD shares.

Brisebois covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Definium Therapeutics, and Savara. According to TipRanks, Brisebois has an average return of 5.5% and a 42.63% success rate on recommended stocks.

In another report released today, Chardan Capital also maintained a Buy rating on the stock with a $13.00 price target.